tetano
Editor, Senior Moderator
Nanomedicine. 2012 Nov 21. pii: S1549-9634(12)00609-0. doi: 10.1016/j.nano.2012.11.001. [Epub ahead of print]
Development of a nanoparticle-based influenza vaccine using the PRINT? technology.
Galloway AL, Murphy A, Desimone JM, Di J, Herrmann JP, Hunter ME, Kindig JP, Malinoski FJ, Rumley MA, Stoltz DM, Templeman TS, Hubby B.
Source
Liquidia Technologies, Inc., Research Triangle Park, NC 27709.
Abstract
Historically it is known that presentation of vaccine antigens in particulate form, for a wide range of pathogens, has clear advantages over the presentation of soluble antigen alone.(1, 2) Herein we describe a novel particle-based approach, which independently controls size, shape, and composition to control the delivery and presentation of vaccine antigen to the immune system. Highly uniform particles were produced using a particle molding technology called PRINT? (Particle Replication in Non-wetting Templates) which is an off-shoot of imprint lithography.(3-10) Cylindrical (diameter [d] = 80 nm, height [h] = 320 nm) poly (lactide-co-glycolide) (PLGA) based PRINT particles were designed to electrostatically bind commercial trivalent injectable influenza vaccine. In a variety of blended PLGA formulations, these particles were safe and showed enhanced responses to influenza hemagglutinin in murine models.
Copyright ? 2012. Published by Elsevier Inc.
PMID:
23178283
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23178283
Development of a nanoparticle-based influenza vaccine using the PRINT? technology.
Galloway AL, Murphy A, Desimone JM, Di J, Herrmann JP, Hunter ME, Kindig JP, Malinoski FJ, Rumley MA, Stoltz DM, Templeman TS, Hubby B.
Source
Liquidia Technologies, Inc., Research Triangle Park, NC 27709.
Abstract
Historically it is known that presentation of vaccine antigens in particulate form, for a wide range of pathogens, has clear advantages over the presentation of soluble antigen alone.(1, 2) Herein we describe a novel particle-based approach, which independently controls size, shape, and composition to control the delivery and presentation of vaccine antigen to the immune system. Highly uniform particles were produced using a particle molding technology called PRINT? (Particle Replication in Non-wetting Templates) which is an off-shoot of imprint lithography.(3-10) Cylindrical (diameter [d] = 80 nm, height [h] = 320 nm) poly (lactide-co-glycolide) (PLGA) based PRINT particles were designed to electrostatically bind commercial trivalent injectable influenza vaccine. In a variety of blended PLGA formulations, these particles were safe and showed enhanced responses to influenza hemagglutinin in murine models.
Copyright ? 2012. Published by Elsevier Inc.
PMID:
23178283
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23178283